Skip to content
value.today
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. is listed today as Endra Life Sciences Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of ENDRA Life Sciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$14 MPrivate placement after listing$10 to $50 million

ENDRA Life Sciences Inc.: Private sale, Oct 2025

Investors in this round

6 investors had bought by the notice of Oct 24, 2025: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
$200,000
What was sold
equity, other: Prefunded and Common Warrants to purchase shares of Common Stock
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$295,498
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Tokman · Executive Officer, Director
  • Michael Thornton · Executive Officer
  • Richard Jacroux · Executive Officer
  • Anthony J. DiGiandomenico · Director
  • Louis J. Basenese · Director
  • Michael J. Harsh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lucid Capital Markets, LLC (CRD 000140345) · New York, New YorkSold in AZ, CT, NY

Remarks in the notice

  • On the amounts: “Reflects proceeds from the sale of shares of the Company's common stock, par value $0.0001 per share and/or pre-funded warrants and common stock purchase warrants, if all such warrants were exercised.”

Signed by Alexander Tokman, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 24, 2025. Read the notice at the SEC.

equitySEC
Dec 2019$9 MPrivate placement after listing$2 to $10 million

ENDRA Life Sciences Inc.: Private sale, Dec 2019

Investors in this round

151 investors had bought by the notice of Dec 20, 2019: 151 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
$5,000
What was sold
equity, debt, securities to be acquired by exercising them, other: Offering included shares of preferred stock convertible into common stock, shares of common stock, and warrants exercisable for common stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$766,221
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Wells · Executive Officer
  • Francois R. Michelon · Executive Officer, Director
  • Michael R. Thornton · Executive Officer
  • Alexander S. Tokman · Director
  • Anthony R. DiGiandomenico · Director
  • Michael S. Harsh · Director
  • Sanjiv S. Gambhir · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lake Street Capital Markets, LLC (CRD 164447) · broker-dealer Newbridge Securities Corporation (CRD 104065) · Minneapolis, MinnesotaSold in AR, AZ, CA, CO, CT, DC, FL, GA, IL, MA, MI, MN, MO, NC, NJ, NY, OH, OK, PA, SC, TX, UT, VA, WA, WI

Signed by Francois Michelon, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2019. Read the notice at the SEC.

equity, debtSEC
Jul 2019$3 MPrivate placement after listing$2 to $10 million

ENDRA Life Sciences Inc.: Private sale, Jul 2019

Investors in this round

86 investors had bought by the notice of Jul 31, 2019: 86 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$20,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible promissory notes and shares of common stock issuable upon conversion. Warrants and shares of common stock issuable upon exercise.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$280,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Wells · Executive Officer
  • Francois R. Michelon · Executive Officer, Director
  • Michael R. Thornton · Executive Officer
  • Alexander Y. Tokman · Director
  • Anthony R. DiGiandomenico · Director
  • Michael S. Harsh · Director
  • Sanjiv S. Gambhir · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, New YorkSold in CA, CO, CT, DC, FL, GA, IL, MA, MI, MN, NC, NJ, NY, OK, PA, SC, TX, UT, VA, WA, WI, and outside the US

Signed by Francois Michelon, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 31, 2019. Read the notice at the SEC.

debt, optionsSEC
Jun 2018$1 MPrivate placement after listingUnder $2 million

ENDRA Life Sciences Inc.: Private sale, Jun 2018

Investors in this round

18 investors had bought by the notice of Jul 3, 2018: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered; $0 M still to sell
Smallest investment taken
$50,000
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$107,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Wells · Executive Officer
  • Francois R. Michelon · Executive Officer, Director
  • Michael R. Thornton · Executive Officer
  • Alexander Y. Tokman · Director
  • Anthony R. DiGiandomenico · Director
  • Michael S. Harsh · Director
  • Sanjiv S. Gambhir · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, New YorkSold in AZ, CA, FL, IL, MI, NJ, NY, WA, WI

Signed by Francois Michelon, President and CEO. Source: SEC Form D, newest notice filed Jul 3, 2018. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ENDRA Life Sciences Inc. had no revenue when it filed its newest notice of a funding round (Oct 2025).

    SEC Form D (revenue range) · Oct 2025

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2018; revenue of up to $1 million in 2019; no revenue in 2025.

    SEC Form D (revenue range) · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

Products and services#

No products or services of ENDRA Life Sciences Inc. are on record.

Investors#

No investor of ENDRA Life Sciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Endra Life Sciences Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ENDRA Life Sciences Inc.
NameRoleNamed in
Alexander TokmanExecutive officerOct 2025
Michael ThorntonExecutive officerOct 2025
Richard JacrouxExecutive officerOct 2025
David R. WellsExecutive officerDec 2019
Francois R. MichelonExecutive officerDec 2019
Michael R. ThorntonExecutive officerDec 2019
Alexander TokmanDirectorOct 2025
Anthony J. DiGiandomenicoDirectorOct 2025
Louis J. BaseneseDirectorOct 2025
Michael J. HarshDirectorOct 2025
Alexander S. TokmanDirectorDec 2019
Anthony R. DiGiandomenicoDirectorDec 2019
Francois R. MichelonDirectorDec 2019
Michael S. HarshDirectorDec 2019
Sanjiv S. GambhirDirectorDec 2019
Alexander Y. TokmanDirectorJul 2019

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.